Analysts UBS upgrade Eli Lilly (LLY) target price to $1,550 and reiterate buy rating
Several analysts have made significant upgrades and downgrades to various stocks, reflecting changing market conditions and company performances. Notably, Eli Lilly's price target was raised, while Yeti was downgraded, indicating a shift in investor sentiment towards these companies.